Artal Group’s Blueprint Medicines BPMC Stock Holding History

Artal Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100,000	Closed	-$10.3M	–	154
2021 Q3	$10.3M	Hold	100,000	–	–	0.23%	80
2021 Q2	$8.8M	Buy	+100,000	New	+$9.16M	0.18%	92
2020 Q3	–	Sell	-550,000	Closed	-$42.9M	–	142
2020 Q2	$42.9M	Buy	550,000 +150,000	+38%	+$10.1M	1.2%	21
2020 Q1	$23.4M	Hold	400,000	–	–	0.99%	27
2019 Q4	$32M	Sell	400,000 -200,000	-33%	-$15M	1.24%	16
2019 Q3	$44.1M	Sell	600,000 -150,000	-20%	-$13M	1.77%	13
2019 Q2	$70.7M	Sell	750,000 -100,000	-12%	-$8.25M	2.86%	7
2019 Q1	$68M	Buy	850,000 +250,000	+42%	+$18.5M	2.78%	9
2018 Q4	$32.3M	Buy	600,000 +100,000	+20%	+$6.08M	1.2%	19
2018 Q3	$39M	Sell	500,000 -200,000	-29%	-$13.9M	1.02%	18
2018 Q2	$44.4M	Buy	700,000 +250,000	+56%	+$19.9M	0.94%	15
2018 Q1	$41.3M	Buy	450,000 +350,000	+350%	+$30.2M	0.52%	20
2017 Q4	$7.54M	Buy	+100,000	New	+$7.04M	0.11%	56

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artal Group's BPMC Position: Q4 2021 in Review

Artal Group sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 100,000 shares — an estimated $10.3M sold.

Artal Group first reported a position in BPMC in Q4 2017 and held it in 13 quarters. The position peaked at $70.7M in Q2 2019. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

Artal Group reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
Artal Group sold 100,000 Blueprint Medicines shares in Q4 2021, an estimated $10.3M.
Artal Group first reported a position in Blueprint Medicines in Q4 2017 and held it in 13 quarters.
Artal Group's Blueprint Medicines position peaked at $70.7M in Q2 2019.
280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.